Siponimod for Secondary Progressive Multiple Sclerosis (920)
Warning
Siponimod (Mayzent®) is accepted for use within NHS Scotland for the treatment of adult
patients with secondary progressive multiple sclerosis (SPMS) with active disease
evidenced by relapses (in the past 1 year) and / or imaging features of inflammatory
activity. This will be defined as new T2 lesions / contrasting enhancement / enlarging T2
lesion on MRI scan (at least one lesion within 1 year).
In a randomised, double-blind, placebo-controlled phase III study, siponimod was
associated with a reduction in disability progression confirmed after 3 months in patients with SPMS. Siponimod reduced the risk of 6-month confirmed disability progression by 26% compared to placebo.